Liver Update: Screening diabetic patients for NAFLD with controlled attenuation parameter and liver stiffness measurements
eMediNexus, 24 November 2021
remove_red_eye 1255 Views
#Gastroenterology #Hepatology #Multispeciality
Coronavirus Live Count Map India
remove_red_eye 1255 Views
COVID-19 Vaccine Updates
Coronavirus Protocols
#Gastroenterology #Hepatology #Multispeciality
Type 2 diabetes increases the risk for non-alcoholic fatty liver disease (NAFLD), but current guidelines do not clearly explain screening for NAFLD in diabetic patients. A study investigated the strategy of screening diabetic patients by FibroScan.Controlled attenuation parameter (CAP) and liver stiffness measurements (LSM) were used for assessing Liver fat and fibrosis by FibroScan. Advanced fibrosis was identified by Probe-specific LSM cut-offs.The observations of the study were as follows-191...
Create Account
Login Now
To read the complete article ,
create a free account.
Sign Up
to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
Presentation is very well...it explained need of hour..